U.S. Stem Cell, Inc. - 10-K/A filing on 2022-07-08

SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 16 — SUBSEQUENT EVENTS In January 2022, the Company issued 1,951,207 common shares in exchange for services rendered. In February, 2022 the company issued 3,125,000 common shares for a subscription agreement. In February 2022, the Company issued 20,000,000 common shares in exchange for services rendered. From February 17, 2022 through February 26, 2022, the Company defaulted on convertible notes payable with an aggregate face value of $419,000. The Company extended the maturity date of $234,000 of these convertible notes with an incentive stock issuance of 56,525,000 common shares and 12,500,000 warrant issued. The Company fully converted $25,000 into 3,125,000 common stock. The Company defaulted on $205,000 of convertible notes to which 12% interest was added commencing at the respective maturity date.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2021

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 16 — SUBSEQUENT EVENTS

In January 2022, the Company issued 1,951,207 common shares in exchange for services rendered.

In February, 2022 the company issued 3,125,000 common shares for a subscription agreement.

In February 2022, the Company issued 20,000,000 common shares in exchange for services rendered.

From February 17, 2022 through February 26, 2022, the Company defaulted on convertible notes payable with an aggregate face value of $419,000. The Company extended the maturity date of $234,000 of these convertible notes with an incentive stock issuance of 56,525,000 common shares and 12,500,000 warrant issued. The Company fully converted $25,000 into 3,125,000 common stock. The Company defaulted on $205,000 of convertible notes to which 12% interest was added commencing at the respective maturity date.